Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism alteration regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease

References

• Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741–27. doi:10.1016/S0140-6736(16)31711-1.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010;139(6):1816–1819. doi:10.1053/j.gastro.2010.10.036.
   PubMed Web of Science ®Google Scholar
• Veny M, Fernández-Clotet A, Panés J. Controlling leukocyte trafficking in IBD. Pharmacol Res. 2020;159:105050. doi:10.1016/j.phrs.2020.105050.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Hibi T. Improving IBD outcomes in the era of many treatment options. Nat Rev Gastroenterol Hepatol. 2023;20(2):79–80. doi:10.1038/s41575-022-00738-z.
   PubMed Web of Science ®Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–1444. doi:10.1093/ecco-jcc/jjw092.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B, Lukas, M, Fedorak, RN and Lee, S, Bressler, B, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711‐721. doi:10.1056/NEJMoa1215739.
   Web of Science ®Google Scholar
• Vermeire S, Loftus EV Jr, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D’Haens GR, Kaser A, Panaccione R. et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohns Colitis. 2017;11(4):412–424. doi:10.1093/ecco-jcc/jjw176.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N. et al. Association of vedolizumab level, anti-drug antibodies, and α4β7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(5):697–705 e7. doi:10.1016/j.cgh.2017.11.050.
   PubMed Web of Science ®Google Scholar
• Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M. et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68(1):25–39. doi:10.1136/gutjnl-2018-316023.
   PubMed Web of Science ®Google Scholar
• Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 2012;3(6):544–555. doi:10.4161/gmic.22156.
   PubMed Web of Science ®Google Scholar
• Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer M-A, Swidsinski A, Beaugerie L, Colombel J-F. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127(2):412–421. doi:10.1053/j.gastro.2004.04.061.
   PubMed Web of Science ®Google Scholar
• Elhenawy W, Oberc A, Coombes BK. A polymicrobial view of disease potential in Crohn’s-associated adherent-invasive E. coli. Gut Microbes. 2018;9(2):166–174. doi:10.1080/19490976.2017.1378291.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet J-P, Corthier G. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736. doi:10.1073/pnas.0804812105.
   PubMed Web of Science ®Google Scholar
• Quevrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, Miquel S, Carlier L, Bermúdez-Humarán LG, Pigneur B. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut. 2016;65(3):415–425. doi:10.1136/gutjnl-2014-307649.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host & Microbe. 2017;21(5):603–610 e3. doi:10.1016/j.chom.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Dorrestein PC, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity. 2014;40(6):824–832. doi:10.1016/j.immuni.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Lesley, S, Peters, EC, Siuzdak, G, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106(10):3698–3703. doi:10.1073/pnas.0812874106.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22–39. doi:10.1080/19490976.2015.1127483.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick RB, Green MD, Hagey LR, Hofmann AF, Tephly TR. Effect of side chain length on bile acid conjugation: glucuronidation, sulfation and coenzyme a formation of nor-bile acids and their natural C24 homologs by human and rat liver fractions. Hepatology. 1988;8(2):353–357. doi:10.1002/hep.1840080227.
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 2011;54(4):1421–1432. doi:10.1002/hep.24525.
   PubMed Web of Science ®Google Scholar
• Greve JW, Gouma DJ, Buurman WA. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study. Hepatology. 1989;10(4):454–458. doi:10.1002/hep.1840100409.
   PubMed Web of Science ®Google Scholar
• Pols TW, Nomura M, Harach T, Sasso GL, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R. et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747–757. doi:10.1016/j.cmet.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper D, Bertin J, Eisenbarth S, Gordon J. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145(5):745–757. doi:10.1016/j.cell.2011.04.022.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Knight R. Species divergence and the measurement of microbial diversity. FEMS Microbiol Rev. 2008;32(4):557–578. doi:10.1111/j.1574-6976.2008.00111.
   PubMed Web of Science ®Google Scholar
• McCafferty J, Mühlbauer M, Gharaibeh RZ, Arthur JC, Perez-Chanona E, Sha W, Jobin C, Fodor AA. Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model. ISME J. 2013;7(11):2116–2125. doi:10.1038/ismej.2013.106.
   PubMed Web of Science ®Google Scholar
• Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood. 2011;117(11):3076–3086. doi:10.1182/blood-2010-08-301507.
   PubMed Web of Science ®Google Scholar
• Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24(10):1785–1788. doi:10.1038/leu.2010.158.
   PubMed Web of Science ®Google Scholar
• Kiesler P, Fuss IJ, Strober W. Experimental models of inflammatory bowel diseases. Cell Mol Gastroenterol Hepatol. 2015;1(2):154–170. doi:10.1016/j.jcmgh.2015.01.006.
   PubMed Web of Science ®Google Scholar
• Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12(7):1295–1309. doi:10.1038/nprot.2017.044.
   PubMed Web of Science ®Google Scholar
• Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D. et al. Combination of vedolizumab with tacrolimus is more efficient than vedolizumab alone in the treatment of experimental colitis. Inflamm Bowel Dis. 2021;27(12):1986–1998. doi:10.1093/ibd/izab063.
   PubMed Web of Science ®Google Scholar
• Yousefi-Ahmadipour A, Rashidian A, Mirzaei MR, Farsinejad A, PourMohammadi-Nejad F, Ghazi-Khansari M, Ai J, Shirian S, Allahverdi A, Saremi J. et al. Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: the S1P pathway. J Cell Physiol. 2019;234(7):11078–11091. doi:10.1002/jcp.27944.
   PubMed Web of Science ®Google Scholar
• Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996;39(3):407–415. doi:10.1136/gut.39.3.407.
   PubMed Web of Science ®Google Scholar
• Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine. 2018;30:317–325. doi:10.1016/j.ebiom.2018.03.030.
   PubMed Web of Science ®Google Scholar
• Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60. doi:10.1186/gb-2011-12-6-r60.
   PubMed Web of Science ®Google Scholar
• Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293–305. doi:10.1038/s41564-018-0306-4.
   PubMed Web of Science ®Google Scholar
• Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, Holmes E, Nicholson JK. Global metabolic profiling procedures for urine using UPLC–MS. Nat Protoc. 2010;5(6):1005–1018. doi:10.1038/nprot.2010.50.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Assche GV, Baert F, Bulois P, Maunoury V. et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512. doi:10.1016/s0016-5107(04)01878-4.
   PubMed Web of Science ®Google Scholar
• Elliott PR, Lennard-Jones JE, Hathway N. A simple index of Crohn’s-disease activity. Lancet. 1980;1(8173):876. doi:10.1016/s0140-6736(80)91372-0.
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JWD. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994;106(2):287–296. doi:10.1016/0016-5085(94)90585-1.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Bruss A, Moosreiner A, Beniwal-Patel P, Nunez L, Berens B, Colombel JF, Targan SR, Fox C, Melmed GY. et al. Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: results of the constellation study. Gastroenterology. 2023;165(4):963–975.e5. doi:10.1053/j.gastro.2023.06.036.
   PubMed Web of Science ®Google Scholar
• Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A. Antibodies toward vedolizumab appear from the first infusion onward and disappear over time. Inflamm Bowel Dis. 2017;23(12):2202–2208. doi:10.1097/MIB.0000000000001255.
   PubMed Web of Science ®Google Scholar
• Wei SD, Brejnrod AD, Trivedi U, Mortensen MS, Johansen MY, Karstoft K, Vaag AA, Ried-Larsen M, Sørensen SJ. Impact of intensive lifestyle intervention on gut microbiota composition in type 2 diabetes: a post-hoc analysis of a randomized clinical trial. Gut Microbes. 2022;14(1):2005407. doi:10.1080/19490976.2021.2005407.
   PubMed Web of Science ®Google Scholar
• Jayaraj P, Narasimhulu CA, Maiseyeu A, Durairaj R, Rao S, Rajagopalan S, Parthasarathy S, Desikan R. Methoxyphenol derivatives as reversible inhibitors of myeloperoxidase as potential antiatherosclerotic agents. Future Med Chem. 2020;12(2):95–110. doi:10.4155/fmc-2019-0080.
   PubMed Web of Science ®Google Scholar
• Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–539. doi:10.1136/gutjnl-2012-302578.
   PubMed Web of Science ®Google Scholar
• Cowen AE, Korman MG, Hofmann AF, Cass OW, Coffin SB. Metabolism of lithocholate in healthy man. II. Enterohepatic circulation. Gastroenterology. 1975;69(1):67–76. doi:10.1016/S0016-5085(19)32637-X.
   PubMed Web of Science ®Google Scholar
• Huijghebaert SM, Eyssen HJ. Specificity of bile salt sulfatase activity from Clostridium sp. strains S1. Appl Environ Microbiol. 1982;44(5):1030–1034. doi:10.1128/aem.44.5.1030-1034.1982.
   PubMed Web of Science ®Google Scholar
• Huijghebaert S, Parmentier G, Eyssen H. Specificity of bile salt sulfatase activity in man, mouse and rat intestinal microflora. J Steroid Biochem. 1984;20(4A):907–912. doi:10.1016/0022-4731(84)90404-7.
   PubMedGoogle Scholar
• Jia W, Xie GX, Jia WP. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–128. doi:10.1038/nrgastro.2017.119.
   PubMed Web of Science ®Google Scholar
• Hua YL, Jia YQ, Zhang XS, Yuan ZW, Ji P, Hu JJ, Wei Y-M. Baitouweng Tang ameliorates DSS-induced ulcerative colitis through the regulation of the gut microbiota and bile acids via pathways involving FXR and TGR5. Biomed Pharmacother. 2021;137:111320. doi:10.1016/j.biopha.2021.111320.
   PubMed Web of Science ®Google Scholar
• Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50(10):1955–1966. doi:10.1194/jlr.R900010-JLR200.
   PubMed Web of Science ®Google Scholar
• Lajczak-McGinley NK, Porru E, Fallon CM, Smyth J, Curley C, McCarron PA, Tambuwala MM, Roda A, Keely SJ. The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis. Physiol Rep. 2020;8(12):e14456. doi:10.14814/phy2.14456.
   PubMed Web of Science ®Google Scholar
• Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, Matsuoka K. et al. TGR 5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology. 2013;139(1):19–29. doi:10.1111/imm.12045.
   PubMed Web of Science ®Google Scholar
• Sun X, Winglee K, Gharaibeh RZ, Gauthier J, He Z, Tripathi P, Avram D, Bruner S, Fodor A, Jobin C. et al. Microbiota-derived metabolic factors reduce campylobacteriosis in mice. Gastroenterology. 2018;154(6):1751–1763 e2. doi:10.1053/j.gastro.2018.01.042.
   PubMed Web of Science ®Google Scholar
• Strauch ED, Yamaguchi J, Bass BL, Wang JY. Bile salts regulate intestinal epithelial cell migration by nuclear factor-kappa B-induced expression of transforming growth factor-beta. J Am Coll Surg. 2003;197(6):974–984. doi:10.1016/S1072-7515(03)00720-8.
   PubMed Web of Science ®Google Scholar
• Sun J, Mustafi R, Cerda S, Chumsangsri A, Xia YR, Li YC, Bissonnette M. Lithocholic acid down-regulation of NF-κB activity through vitamin D receptor in colonic cancer cells. J Steroid Biochem Mol Biol. 2008;111(1–2):37–40. doi:10.1016/j.jsbmb.2008.01.003.
   PubMed Web of Science ®Google Scholar
• Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108(2):225–246. doi:10.1093/toxsci/kfn268.
   PubMed Web of Science ®Google Scholar
• Hamilton JP, Xie G, Raufman JP, Hogan S, Griffin TL, Packard CA, Chatfield DA, Hagey LR, Steinbach JH, Hofmann AF. et al. Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):G256–263. doi:10.1152/ajpgi.00027.2007.
   PubMed Web of Science ®Google Scholar
• Van Eldere J, Robben J, De Pauw G, Merckx R, Eyssen H. Isolation and identification of intestinal steroid-desulfating bacteria from rats and humans. Appl Environ Microbiol. 1988;54(8):2112–7. doi:10.1128/aem.54.8.2112-2117.1988.
   PubMed Web of Science ®Google Scholar
• Meinl W, Sczesny S, Brigelius-Flohé R, Blaut M, Glatt H. Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat. Drug Metab Dispos. 2009;37(6):1179–1186. doi:10.1124/dmd.108.025916.
   PubMed Web of Science ®Google Scholar
• Vázquez-Baeza Y, Gonzalez A, Xu ZZ, Washburne A, Herfarth HH, Sartor RB, Knight R. Guiding longitudinal sampling in IBD cohorts. Gut. 2018;67(9):1743–1745. doi:10.1136/gutjnl-2017-315352.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201. doi:10.1053/j.gastro.2011.06.054.
   PubMed Web of Science ®Google Scholar
• Pavlidis P, Gulati S, Dubois P, Chung-Faye G, Sherwood R, Bjarnason I, Hayee B. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease. Scand J Gastroenterol. 2016;51(12):1447–1452. doi:10.1080/00365521.2016.1205128.
   PubMed Web of Science ®Google Scholar